- Home
- WOOF vs GYRE Comparison
WOOF vs GYRE Comparison
Compare WOOF & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOOF
- GYRE
- Stock Information
- Founded
- WOOF 1965
- GYRE 2002
- Country
- WOOF United States
- GYRE United States
- Employees
- WOOF N/A
- GYRE N/A
- Industry
- WOOF Other Specialty Stores
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- WOOF Consumer Discretionary
- GYRE Health Care
- Exchange
- WOOF Nasdaq
- GYRE Nasdaq
- Market Cap
- WOOF 1.0B
- GYRE 997.3M
- IPO Year
- WOOF 2021
- GYRE N/A
- Fundamental
- Price
- WOOF $2.91
- GYRE $11.54
- Analyst Decision
- WOOF Buy
- GYRE
- Analyst Count
- WOOF 11
- GYRE 0
- Target Price
- WOOF $4.16
- GYRE N/A
- AVG Volume (30 Days)
- WOOF 3.8M
- GYRE 53.5K
- Earning Date
- WOOF 03-26-2025
- GYRE 03-25-2025
- Dividend Yield
- WOOF N/A
- GYRE N/A
- EPS Growth
- WOOF N/A
- GYRE N/A
- EPS
- WOOF N/A
- GYRE N/A
- Revenue
- WOOF $6,238,808,000.00
- GYRE $105,033,000.00
- Revenue This Year
- WOOF $0.24
- GYRE $25.32
- Revenue Next Year
- WOOF $2.44
- GYRE $12.95
- P/E Ratio
- WOOF N/A
- GYRE N/A
- Revenue Growth
- WOOF 1.30
- GYRE N/A
- 52 Week Low
- WOOF $1.41
- GYRE $8.26
- 52 Week High
- WOOF $6.29
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- WOOF 32.74
- GYRE 47.99
- Support Level
- WOOF $2.65
- GYRE $12.09
- Resistance Level
- WOOF $3.13
- GYRE $12.80
- Average True Range (ATR)
- WOOF 0.19
- GYRE 0.56
- MACD
- WOOF -0.00
- GYRE -0.00
- Stochastic Oscillator
- WOOF 33.77
- GYRE 16.39
About WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet health and wellness company focused on improving the lives of pets, pet parents, and its partners with approximately 1,423 pet care centers offering pet care products such as puppy food, treats, nutrition, and supplies through retail outlets and online platforms. The company generates revenue from the sale of products and services such as dog and cat food, supplies, and companion animals, among others.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.